Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
Gastroenterology
|
July 15, 2009
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab
William J Sandborn, Paul Rutgeerts, Brian G Feagan, et al.
Alimentary Pharmacology & Therapeutics
|
January 11, 2022
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis
Silvio Danese, Barrett G Levesque, Brian G Feagan, et al.
Alimentary Pharmacology & Therapeutics
|
March 4, 2022
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply
Silvio Danese, Barrett G Levesque, Brian G Feagan, et al.
Gut
|
August 5, 2018
Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial
Vipul Jairath, Laurent Peyrin-Biroulet, Guangyong Zou, et al.
European Journal of Heart Failure
|
March 9, 2013
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction
Mihai Gheorghiade, Stephen J Greene, Piotr Ponikowski, et al.
Gastroenterology
|
November 6, 2018
RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis
Ikuo Hirano, Margaret H Collins, Yehudith Assouline-Dayan, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
Gastroenterology
|
July 15, 2009
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab
William J Sandborn, Paul Rutgeerts, Brian G Feagan, et al.
Alimentary Pharmacology & Therapeutics
|
January 11, 2022
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis
Silvio Danese, Barrett G Levesque, Brian G Feagan, et al.
Alimentary Pharmacology & Therapeutics
|
March 4, 2022
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply
Silvio Danese, Barrett G Levesque, Brian G Feagan, et al.
Gut
|
August 5, 2018
Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial
Vipul Jairath, Laurent Peyrin-Biroulet, Guangyong Zou, et al.
European Journal of Heart Failure
|
March 9, 2013
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction
Mihai Gheorghiade, Stephen J Greene, Piotr Ponikowski, et al.
Gastroenterology
|
November 6, 2018
RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis
Ikuo Hirano, Margaret H Collins, Yehudith Assouline-Dayan, et al.
Page
of 3